Table 1. Baseline characteristics of study participants.
| HIV-infected pts (n = 500) | HIV-uninfected pts (n = 500) | ||
| n (% or IQR) | n (% or IQR) | p value | |
| Characteristic | |||
| Median Age, years | 38 (IQR 31–44) | 37 (IQR 32–44) | 0.025 |
| Female | 312 (67%) | 333 (67%) | 0.89 |
| Heavy Liquor use (>1.25 L/week) | 11 (2%) | 9 (2%) | 0.65 |
| Lifetime occupational fishing | 5 (1%) | 1 (0.2%) | 0.65 |
| HBsAg positive | 23 (5%) | 14 (3%) | 0.10 |
| Valid TE scan | 468 (94%) | 494 (99%) | <0.001 |
| Herb Use | |||
| Current herb use | 8 (2%) | 33 (7%) | 0.0001 |
| Known herbs | 5 (0.9%) | 16 (3%) | 0.015 |
| Unknown herbs | 4 (0.9%) | 17 (3%) | 0.004 |
| Asteraceae family | 2 (0.4%) | 6 (1%) | 0.16 |
| Fabaceae family | 0 (0%) | 6 (1%) | 0.014 |
| Lamiaceae family | 1 (0.2%) | 4 (0.8%) | 0.18 |
| ACTG Heptatotoxicty Criteria | |||
| Median ALT (U/L) | 22 (IQR 16–31) | 19 (IQR 15–25) | <0.001 |
| Grade 0 (<1.25×ULN) by ALT | 354 (71%) | 414 (83%) | |
| Grade 1 (1.25–2.5×ULN) by ALT | 122 (24%) | 77 (15%) | |
| Grade 2 (2.6–5×ULN) by ALT | 19 (4%) | 9 (2%) | |
| Grade 3 (5.1–10×ULN) by ALT | 5 (1%) | 0 (0%) | |
| Grade 4 (>10×ULN) by ALT | 0 (0%) | 0 (0%) | |
| CD4 and ART Characteristics | |||
| Current CD4 count (cells/uL) | 449 (IQR 320–642) | ||
| Nadir CD4 count (cells/uL) | 214 (IQR 130–350) | ||
| Nadir CD4 count <100 cells/uL | 95 (19%) | ||
| On ART | 302 (60%) | ||
| ART duration (months) | 19 (IQR 9–38) | ||
HIV (Human Immunodeficiency Virus), IQR (Interquartile Range), HBsAg (Hepatitis B Surface Antigen), ACTG (AIDS Clinical Trials Group), CD4 (Cluster of Differentiation 4 positive Helper T cells), ART (Antiretroviral Therapy).